Literature DB >> 6269789

Ranitidine kinetics and dynamics. II. Intravenous dose studies and comparison with cimetidine.

P A Lebert, W A Mahon, S M MacLeod, S J Soldin, P Fenje, H M Vandenberghe.   

Abstract

Intravenous ranitidine has been shown to reduce pentagastrin-stimulated gastric secretion. Eight normal men received, in randomized order, 60 mg ranitidine or 300 mg cimetidine intravenously over 2 min. Both ranitidine and cimetidine induced decreases in volume hydrogen ion content and pepsin activity of stimulated gastric juice. Ranitidine half-life (t1/2) was 2.1 +/- 0.1 hr and cimetidine (t1/2) was 1.5 +/- 0.1 hr. Ranitidine volume of distribution was 1.6 +/- 0.1 l/kg and that of cimetidine was 1.12 +/- 0.12 l/kg. The clearance of ranitidine was 0.54 +/- 0.04 l/kg hr-1 and that of cimetidine was 0.5 +/- 0.05 l/kg hr-1. It is suggested that the intravenous loading dose of ranitidine necessary to attain a serum concentration of 200 micrograms/l (which would achieve a 50% inhibition of gastric acid) is 0.3 mg/kg, followed by an infusion rate of 0.11 mg/kg hr-1.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6269789     DOI: 10.1038/clpt.1981.201

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

2.  Pharmacokinetics of cimetidine after subchronic administration.

Authors:  T W Chin; M Spino; S M MacLeod; W A Mahon; S J Soldin
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Pharmacokinetics and bioavailability of ranitidine in normal subjects and cirrhotic patients.

Authors:  M Morichau-Beauchant; G Houin; P Mavier; C Alexandre; D Dhumeaux
Journal:  Dig Dis Sci       Date:  1986-02       Impact factor: 3.199

4.  Pharmacokinetics of mifentidine after single and multiple oral administration to healthy volunteers.

Authors:  B P Imbimbo; R Urso; G Thieme; B Sturn; B Ueckert; A Vidi; H Ladinsky; S Daniotti
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

Review 5.  Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

Review 6.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

Review 7.  Clinical pharmacokinetics of ranitidine.

Authors:  C J Roberts
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

8.  Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis.

Authors:  D A Sica; T Comstock; A Harford; F Eshelman
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 9.  Clinical pharmacokinetics of cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1983 Nov-Dec       Impact factor: 6.447

Review 10.  Interactions and non-interactions with ranitidine.

Authors:  W Kirch; H Hoensch; H D Janisch
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.